Related Experiment Videos
Cerebral and ocular toxicity induced by desferrioxamine
The Quarterly Journal of Medicine
|July 1, 1985
Summary
Iron-chelating drug desferrioxamine (DFX) combined with prochlorperazine caused severe neurological issues in rheumatoid disease patients. Retinal problems also occurred in some patients without prochlorperazine.
Area of Science:
- Neuroscience
- Ophthalmology
- Pharmacology
Background:
- Investigating the anti-inflammatory potential of desferrioxamine (DFX), an iron-chelating drug, in rheumatoid disease patients.
- Assessing the safety profile of DFX in this patient cohort.
Observation:
- Two patients receiving DFX and prochlorperazine experienced prolonged unconsciousness and EEG abnormalities indicative of metabolic disturbance.
- One patient developed pyramidal signs, optic neuropathy, and pigmentary retinopathy, with cerebrospinal fluid analysis revealing altered iron and copper levels and increased lipid peroxidation.
- Two patients not on prochlorperazine developed reversible retinal issues after DFX treatment.
Findings:
- Neurological adverse effects were attributed to a synergistic interaction between desferrioxamine and prochlorperazine, likely causing significant iron and copper fluxes that disrupted neurotransmitter systems.
- DFX alone, at a cumulative dose of 15g, was associated with retinal problems in one patient, suggesting a potential ocular toxicity independent of prochlorperazine.
Implications:
- Highlights a novel model for studying metabolic encephalopathy.
- Provides critical insights into the mechanisms underlying DFX-induced optic neuropathy and pigmentary retinopathy.
- Underscores the importance of careful patient monitoring for neurological and ocular side effects when using DFX, especially in combination with other drugs.